Muscles Become Digital Interfaces: Noxon Closes Seed Funding Round

• Noxon, a Munich-based MedTech spin-off from three leading universities, has closed a multi-million-euro seed funding round.
• The funding will accelerate development of a non-invasive, wearable Muscle-Computer Interface that turns muscles into digital and programmable interfaces for the first time.
• The technology decodes and controls human movement – from reducing Parkinson’s tremor and restoring motor function after paralysis to performance analysis in elite sports.
• As a modular platform, Noxon targets a market of over 1.1 billion people affected by muscle-related conditions and is setting new standards in rehabilitation, neurology, and wearable MedTech.

Noxon, a MedTech company based in Munich and a spin-off from three renowned universities, has successfully closed its seed funding round. The round was led by High-Tech Gründerfonds (HTGF) and Bayern Kapital, two of the leading venture capital investors in Germany and Europe, together with Auxxo and another institutional investor. The capital will be used to advance the clinical validation and certification of Noxon’s non-invasive Muscle-Computer Interface and to prepare for the market launch of its first therapy modules.

In rehabilitation and for neuromuscular disorders, muscle diagnostics and activation are traditionally performed only sporadically and under clinical conditions. As a result, patients lack continuous data and adaptive therapy in their daily lives throughout the treatment process.

Noxon addresses this gap with a medical Muscle-Computer Interface that, for the first time, combines continuous muscle diagnostics and neuromuscular electrical stimulation (NMES) in a wearable suitable for everyday use. The key innovation lies in the closed feedback loop of real-time measurement and personalized muscle and nerve activation over the course of therapy, seamlessly integrated into existing products such as tapes, patches, and orthopedic aids.

Noxon is also collaborating with leading medical partners, including the University Hospital Würzburg and the neuroscience group N-Squared Lab, on additional pilot applications. The focus is on supporting muscle control when signal transmission between the brain and muscle is impaired, such as with solutions that reduce tremor in Parkinson’s patients.

“Neurological and musculoskeletal diseases are on the rise globally. Healthy muscle function is fundamental, yet often overlooked, and existing solutions tend to be too complex or costly,” says Maria Neugschwender, CEO of Noxon. “The support from HTGF and Bayern Kapital enables us to further validate our platform technology clinically and bring our first products to market. Our goal is to make muscle health transparent, personalized, and affordable for everyone.”

Dr. Lena-Sophie Schütter, Investment Manager at HTGF, adds: “What I find so compelling about Noxon is how effective therapy can become as simple as applying a bandage. The Muscle-Computer Interface platform gives patients the opportunity to regain mobility and independence, from preventing muscle atrophy to reducing Parkinson’s tremor. That’s a true advance for quality of life.”

Monika Steger, Managing Director of Bayern Kapital, comments: “Noxon’s technology platform, which enables human muscles to be both ‘read’ and then stimulated and activated, holds significant potential across a range of applications, particularly in therapy and medical rehabilitation. Based on this approach, conditions that are currently difficult to treat, such as Parkinson’s or paralysis, could be addressed more effectively and gently for patients. This would represent major value for both medical technology and healthcare as a whole, making Noxon a very promising investment.”

About Noxon
Founded in 2022, Noxon is a MedTech company focused on non-invasive neuro- and muscle technologies. Its mission is to integrate evidence-based, digital care concepts into both clinical practice and everyday life.

About HTGF – High-Tech Gründerfonds
HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed around 800 startups and achieved 200 successful exits. HTGF has a fund volume of over 2 billion euros. Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family of-fices. For more information, please visit HTGF.de or follow us on LinkedIn.

About Bayern Kapital
Bayern Kapital is one of the most experienced and financially strong venture capital investors in the DACH region. With around €1.3 billion in assets under management, over 120 active portfolio companies, and ticket sizes of up to €50 million per company, Bayern Kapital is one of the few investors in the market that provides financing from pre-seed to global growth and scale-up rounds from a single source. As a public venture capital investor, Bayern Kapital invests in consortiums with leading national and international venture capital funds and supports tech startups and scaleups as a reliable anchor investor across multiple financing rounds.

Since 1995, Bayern Kapital has financed around 390 startups and scaleups with over €675 million of its own equity capital in areas such as deep tech, life sciences, AI, climate tech, SaaS, new space, and quantum technology. Among the numerous success stories from Bavaria are EGYM, plancq, Isar Aerospace, Tubulis, Marvel Fusion, and OroraTech.